Association of peripartum synthetic oxytocin administration and depressive and anxiety disorders within the first postpartum year

Details

• Alternative Title:
  Depress Anxiety
• Personal Author:
  Kroll-Desrosiers, Aimee R. ; Nephew, Benjamin C. ; Babb, Jessica A. ; Guilarte-Walker, Yurima ; Moore Simas, Tiffany A. ; Deligiannidis, Kristina M.
• Description:
  Background
  
  Due to its potent effects on social behavior, including maternal behavior, oxytocin has been identified as a potential mediator of postpartum depression and anxiety. The objective of this study was to examine the relationship between peripartum synthetic oxytocin administration and the development of depressive and anxiety disorders within the first year postpartum. We hypothesized that women exposed to peripartum synthetic oxytocin would have a reduced risk of postpartum depressive and anxiety disorders compared with those without any exposure.
  
  Methods
  
  Population-based data available through the Massachusetts Integrated Clinical Academic Research Database (MiCARD) was used to retrospectively (2005–2014) examine this relationship and calculate the relative risk of peripartum synthetic oxytocin for the development of postpartum depressive and anxiety disorders in exposed (n=9,684) compared to unexposed (n=37,048) deliveries.
  
  Results
  
  Among deliveries to women with a history of prepregnancy depressive or anxiety disorder, exposure to peripartum oxytocin increased the risk of postpartum depressive or anxiety disorder by 36% (RR: 1.36; 95%CI: 1.20–1.55). In deliveries to women with no history of prepregnancy depressive or anxiety disorder, exposure to peripartum oxytocin increased the risk of postpartum depressive or anxiety disorder by 32% compared to those not exposed (RR: 1.32; 95% CI: 1.23–1.42).
  
  Conclusions
  
  Contrary to our hypothesis, results indicate that women with peripartum exposure to synthetic oxytocin had a higher relative risk of receiving a documented depressive or anxiety disorder diagnosis or antidepressant/anxiolytic prescription within the first year postpartum than women without synthetic oxytocin exposure.
  
  
• Subjects:
  Adolescent Adult Anxiety Disorders Depression, Postpartum Female Humans Middle Aged Oxytocics Oxytocin Peripartum Period Pregnancy Treatment Outcome Young Adult

  More +
• Source:
  Depress Anxiety. 34(2):137-146
• Pubmed ID:
  28133901
• Pubmed Central ID:
  PMC5310833
• Document Type:
  Journal Article
• Funding:
  K99 HD059943/HD/NICHD NIH HHSUnited States/ ; R00 HD059943/HD/NICHD NIH HHSUnited States/ ; UL1 TR000161/TR/NCATS NIH HHSUnited States/ ; U01DP006093/ACL/ACL HHSUnited States/ ; K23 MH097794/MH/NIMH NIH HHSUnited States/ ; L30 MH104713/MH/NIMH NIH HHSUnited States/ ; F32 MH108247/MH/NIMH NIH HHSUnited States/ ; UL1 TR001453/TR/NCATS NIH HHSUnited States/ ; U01 DP006093/DP/NCCDPHP CDC HHSUnited States/
• Volume:
  34
• Issue:
  2
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:3815baa171b9bf998f4c531f55412f66f22bca7afce36cea22d3362a5b83a692
• Download URL:
  https://stacks.cdc.gov/view/cdc/44260/cdc_44260_DS1.pdf
• File Type:
  [PDF - 373.92 KB ]